483 related articles for article (PubMed ID: 17215342)
1. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
Espinel-Ingroff A; Canton E; Gibbs D; Wang A
J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.
Espinel-Ingroff A
J Clin Microbiol; 2006 Oct; 44(10):3616-22. PubMed ID: 16943356
[TBL] [Abstract][Full Text] [Related]
3. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
[TBL] [Abstract][Full Text] [Related]
4. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Neo-Sensitabs diffusion method for determining the antifungal susceptibilities of Cryptococcus gattii isolates, using three different agar media.
Pujol I; Pastor FJ; dos Santos Lazéra M; Guarro J
Rev Iberoam Micol; 2008 Dec; 25(4):215-20. PubMed ID: 19071889
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Etest and Neo-Sensitabs diffusion assays on Mueller-Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole.
Ochiuzzi ME; Santiso GM; Arechavala AI
Med Mycol; 2010 Sep; 48(6):893-6. PubMed ID: 20370370
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Canton E
J Clin Microbiol; 2008 May; 46(5):1793-803. PubMed ID: 18337384
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of Fungitest-, Neo-Sensitabs- and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans.
Swinne D; Raes-Wuytack C; Van Looveren K; Desmet P
Mycoses; 1999; 42(4):231-7. PubMed ID: 10424089
[TBL] [Abstract][Full Text] [Related]
9. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
11. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
12. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
13. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.
Borghi E; Iatta R; Sciota R; Biassoni C; Cuna T; Montagna MT; Morace G
J Clin Microbiol; 2010 Sep; 48(9):3153-7. PubMed ID: 20631105
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates.
Rementeria A; Sanchez-Vargas LO; Villar M; Casals JB; Carrillo-Munoz AJ; Rodriguez Andres C; Eraso E; Quindos G
J Chemother; 2007 Apr; 19(2):172-7. PubMed ID: 17434826
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.
Dannaoui E; Paugam A; Develoux M; Chochillon C; Matheron J; Datry A; Bouges-Michel C; Bonnal C; Dromer F; Bretagne S
Clin Microbiol Infect; 2010 Jul; 16(7):863-9. PubMed ID: 19778296
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation and utility of the E-test and Neo-Sensitabs methods in studying fluconazole yeast susceptibility].
Cantón E; Pemán J; Sastre M; Valentín A; Bosch M; Espinel-Ingroff A
Rev Esp Quimioter; 2006 Sep; 19(3):267-74. PubMed ID: 17099795
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2004 Jan; 42(1):380-3. PubMed ID: 14715784
[TBL] [Abstract][Full Text] [Related]
20. Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole.
Khan ZU; Randhawa HS; Chehadeh W; Chowdhary A; Kowshik T; Chandy R
Int J Antimicrob Agents; 2009 Jun; 33(6):559-63. PubMed ID: 19195846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
